Revenues for the three months ended Dec. 31 were $2.62 billion, up from $2.29 billion in Q4 2023 and above the consensus Wall Street estimate of $2.58 billion.

We took advantage of Elevance Health's share price weakness in the fourth quarter and added modestly to our investment. Click here to read more.

Quest Diagnostics (DGX) came out with quarterly earnings of $2.23 per share, beating the Zacks Consensus Estimate of $2.19 per share. This compares to earnings of $2.15 per share a year ago. These ...

Reports Q4 revenue $2.62B, consensus $2.58B. “In the fourth quarter, we delivered impressive revenue growth of nearly 15%, including ...

Cigna said its medical loss ratio was 87.9% in Q4 2024, compared to 82.2% in the prior-year quarter. For the full-year 2024, MLR was 83.2%, which was still higher compared to the 81.3% its insurance ...

The Fund (Class Z) underperformed its benchmark, the MSCI World Value Index, for the quarter ended December 31, 2024. Read ...

Shares of Elevance Health Inc. ELV shed 1.26% to $400.30 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.47% to 6,039.31 ...